Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Australian Government
Deal Size : $11.0 million
Deal Type : Funding
Australian Government Grants TB Alliance for Drug-Resistant TB Research
Details : Funding supports the NC-009 Pan-Phase 2 trial of TBAJ-876 combined with pretomanid and linezolid for treating drug-sensitive and resistant tuberculosis.
Brand Name : TBAJ-876
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2024
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Australian Government
Deal Size : $11.0 million
Deal Type : Funding
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
Details : TBAJ-876 is a diarylquinoline antibiotic that targets a key enzyme of TB bacteria involved in energy production, it is being evaluated in combination with pretomanid and linezolid, for the treatment for both drug-sensitive and drug-resistant TB.
Brand Name : TBAJ-876
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Remington Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Remington will commercialize the anti-tuberculosis medicine, pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid) in Pakistan...
Brand Name : Pretomanid-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 14, 2023
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Remington Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Telacebec
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Qurient
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license to develop and commercialize Q203 (telacebec), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis and some NTM infectio...
Brand Name : Q203
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : Telacebec
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Qurient
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Brand Name : PA-824
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 06, 2021
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Astellas and TB Alliance have conducted joint research (“Screening PJ”) for exploration of new compounds for Mycobacterium tuberculosis since October 2017. The hit compounds appear to be unique in their structures compared with TB drugs in use or und...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 31, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.
Brand Name : PA-824
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2020
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?